Who makes BBT-401-1S, Single dose?

BBT-401-1S, Single dose is developed by Bridge Biotherapeutics, Inc..

What development phase is BBT-401-1S, Single dose in?

BBT-401-1S, Single dose is in Phase 1.

Last reviewed 2026-04-19 · How we verify

BBT-401-1S, Single dose

Bridge Biotherapeutics, Inc. · Phase 1 active Small molecule

At a glance

Generic name	BBT-401-1S, Single dose
Sponsor	Bridge Biotherapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BBT-401-1S, Single dose CI brief — competitive landscape report
BBT-401-1S, Single dose updates RSS · CI watch RSS
Bridge Biotherapeutics, Inc. portfolio CI